<DOC>
	<DOC>NCT01416987</DOC>
	<brief_summary>This prospective study will collect safety information from more than 600 patients treated with Pergoveris®. During the Post-Marketing Surveillance (PMS) period, data about the patient´s background, patient's medical history, Pergoveris® indication, prior infertility medication, Pergoveris® treatment status, concomitant drugs, all adverse events (regardless of the causal relationship to Pergoveris®) and efficacy (follicular growth and clinical pregnancy) will be collected for study purposes. The post marketing surveillance is based on all cases treated with Pergoveris®.</brief_summary>
	<brief_title>A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Patients, who are eligible for Pergoveris® treatment according to the indication in the national label of Pergoveris®. The national label approved by Korea Food &amp; Drug Administration is "Pergoveris® in association with a follicle stimulating hormone(FSH) preparation is recommended for the stimulation of follicular development in women with severe Luteinizing Hormone (LH) and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level &lt; 1.2 IU/L" According to national label</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>